You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复锐医疗科技(01696.HK):天津星魅生物科技获A轮投资1.09亿元
格隆汇 12-22 21:32

格隆汇12月22日丨复锐医疗科技(01696.HK)发布公告,于2020年12月22日,公司的附属公司复锐医疗天津(作为原股东及A轮投资方)与复星健康基金(苏州)及复星健康基金(天津)(二者的普通合伙人均为复星医药的附属公司)以及目标公司天津星魅生物科技有限公司订立A轮投资协议,内容有关向目标公司累计出资人民币1.09亿元,其中复锐医疗天津同意出资人民币1000万元。

根据A轮投资协议,于A轮投资完成后,倘目标公司拟发行额外股份以筹集资金,且复星健康基金(苏州)及复星健康基金(天津)拟参与此类融资,则复锐医疗天津亦将认购目标公司的额外股份,并按于A轮投资完成后其于目标公司的持股比例额外出资,但复锐医疗天津的最高出资额不超过人民币1036.7万元。因此,复锐医疗天津已向目标公司出资以及已同意根据A轮投资协议出资的总金额为人民币2148.7万元。

天津星魅根据中国法律于2020年九月成立,其业务范围包括在中国开发、分销和销售生物技术产品等。于2020年九月,天津星魅与Raziel订立许可及供应协议,据此,Raziel向天津星魅授出许可,许可天津星魅在中国(包括香港、澳门及台湾地区)开发及商业化RZL012。RZL012用于美容和多种肥胖疾病的治疗。

公司认为,天津星魅投资将使公司能够通过天津星魅与Raziel合作,提高集团的医疗美容技术、专业知识及设计能力;及探索交叉销售机会。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account